About This Study
STAR stands for:
A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia
Patients Who Have Received Prior Therapy With
ATRA (All-trans-retinoic-acid) and Arsenic Trioxide (Trisenox™).
This clinical trial is evaluating the safety and efficacy of Tamibarotene in
Acute Promyelocytic Leukemia patients who have received prior therapy with both
ATRA (Vesanoid™ or Tretinoin™) and Arsenic Trioxide (Trisenox™).
This study has been designated as a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). A Special Protocol Assessment is an agreement with the FDA on the study design, the endpoints of the study, and the data analysis plan.
If you would like to see if you qualify to participate in this Innovive research study, click here.